Cargando…

High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment

BACKGROUND: SLFN11 was reported to be a predictive marker for DNA damage drugs. The study was to investigate whether SLFN11 expression is related to sensitivity to adjuvant oxaliplatin-based treatment in colorectal cancer. METHODS: A tissue microarray, made with specimens from consecutive 261 patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Yanhong, Cai, Yue, Huang, Yan, Yang, Zihuan, Bai, Yang, Liu, Yanlu, Deng, Xiuping, Wang, Jianping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631086/ https://www.ncbi.nlm.nih.gov/pubmed/26525741 http://dx.doi.org/10.1186/s12885-015-1840-6

Ejemplares similares

Mouse Slfn8 and Slfn9 genes complement human cells lacking SLFN11 during the replication stress response
por: Alvi, Erin, et al.
Publicado: (2023)

Mechanistic understanding of human SLFN11
por: Metzner, Felix J., et al.
Publicado: (2022)

SLFN11’s surveillance role in protein homeostasis
por: Murai, Yasuhisa, et al.
Publicado: (2022)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase
por: Garvie, Colin W., et al.
Publicado: (2021)

The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
por: Coleman, Niamh, et al.
Publicado: (2020)

Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma
por: Zoppoli, Gabriele, et al.
Publicado: (2015)

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
por: Murai, Junko, et al.
Publicado: (2016)

SPDR-4 SLFN11 RENDERS MEDULLOBLASTOMA SENSITIVE TO DNA DAMAGE CHEMOTHERAPIES
por: Nakata, Satoshi, et al.
Publicado: (2022)

Modulation of SLFN11 induces changes in DNA Damage response in breast cancer
por: Raynaud, Christophe Michel, et al.
Publicado: (2023)

SLFN5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer
por: Xu, Qiao Ping, et al.
Publicado: (2023)

Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
por: Willis, Sophie E., et al.
Publicado: (2021)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
por: Guedes, Joana G, et al.
Publicado: (2013)

PB1791: SLFN11 REGULATES MULTIPLE PATHWAYS THAT ARE IMPORTANT FOR TREATMENT RESPONSE IN AML
por: Small, Sara, et al.
Publicado: (2023)

SLFN14 gene mutations associated with bleeding
por: Stapley, Rachel J., et al.
Publicado: (2019)

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
por: Ballestrero, Alberto, et al.
Publicado: (2017)

SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing
por: Mezzadra, Riccardo, et al.
Publicado: (2019)

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
por: Winkler, Claudia, et al.
Publicado: (2020)

Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development
por: Moribe, Fumiya, et al.
Publicado: (2021)

SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression
por: Fischietti, Mariafausta, et al.
Publicado: (2022)

The “Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan (CPT-11), Oxaliplatin (LOHP), Continuous Infusion 5-Fluorouracil, and Leucovorin for Colorectal Cancer”
por: Deng, Yanhong
Publicado: (2021)

Prognostic Value of KRAS Exon 3 and Exon 4 Mutations in Colorectal Cancer Patients
por: Guo, Tianan, et al.
Publicado: (2021)

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer
por: Hsu, Hung‐Chih, et al.
Publicado: (2019)

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
por: Kagami, Takuma, et al.
Publicado: (2020)

Methylation of SLFN11 promotes gastric cancer growth and increases gastric cancer cell resistance to cisplatin
por: Peng, Yaojun, et al.
Publicado: (2019)

Study of Clinical Predictive Value and Immune Characterization of SLFN11 in Clear Cell Renal Cell Carcinoma
por: Liu, Yifu, et al.
Publicado: (2021)

Ribosome dysfunction underlies SLFN14-related thrombocytopenia
por: Ver Donck, Fabienne, et al.
Publicado: (2023)

Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy
por: Tsubaki, Masanobu, et al.
Publicado: (2023)

SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway
por: Zhou, Chenhao, et al.
Publicado: (2020)

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
por: Nogales, Vanesa, et al.
Publicado: (2015)

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
por: Winkler, Claudia, et al.
Publicado: (2021)

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
por: Zhao, Ming, et al.
Publicado: (2023)

DNA damage-Induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs
por: Li, Manqing, et al.
Publicado: (2018)

Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer
por: Tserpeli, Victoria, et al.
Publicado: (2021)

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
por: Hezel, A F, et al.
Publicado: (2014)

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

SensiScreen(®) KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations
por: Riva, Alice, et al.
Publicado: (2017)

Survival of patients with KRAS wild-type metastatic colorectal cancer is identical after sequential treatment with cetuximab and bevacizumab regardless of the sequence – A retrospective single-center study
por: Deng, Yanhong, et al.
Publicado: (2015)

Understanding KRAS for better targeting
por: Patel, Ronak, et al.
Publicado: (2023)

No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis
por: Zhou, Si-wei, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7pe0n8jdt04eiq9s8vgjbmgnb2